PCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Pacira BioSciences's current share price is $26.33. Pacira BioSciences's E10 for the quarter that ended in Dec. 2023 was $0.26. Pacira BioSciences's Shiller PE Ratio for today is 101.27.
The historical rank and industry rank for Pacira BioSciences's Shiller PE Ratio or its related term are showing as below:
During the past years, Pacira BioSciences's highest Shiller PE Ratio was 500.88. The lowest was 97.27. And the median was 176.69.
PCRX's Shiller PE Ratio is ranked worse thanE10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Pacira BioSciences's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.520. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.26 for the trailing ten years ended in Dec. 2023.
The historical data trend for Pacira BioSciences's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | 519.09 | 190.82 | 128.70 |
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Pacira BioSciences's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 26.33 | / | 0.26 | |
= | 101.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences's E10 for the quarter that ended in Dec. 2023 is calculated as:
For example, Pacira BioSciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.52 | / | 129.4194 | * | 129.4194 | |
= | 0.520 |
Current CPI (Dec. 2023) = 129.4194.
Pacira BioSciences Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201403 | -0.340 | 99.695 | -0.441 |
201406 | -0.140 | 100.560 | -0.180 |
201409 | -0.080 | 100.428 | -0.103 |
201412 | 0.140 | 99.070 | 0.183 |
201503 | 0.030 | 99.621 | 0.039 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.080 | 100.392 | 0.103 |
201512 | -0.070 | 99.792 | -0.091 |
201603 | -0.100 | 100.470 | -0.129 |
201606 | -0.210 | 101.688 | -0.267 |
201609 | -0.590 | 101.861 | -0.750 |
201612 | -0.110 | 101.863 | -0.140 |
201703 | -0.520 | 102.862 | -0.654 |
201706 | -0.490 | 103.349 | -0.614 |
201709 | -0.190 | 104.136 | -0.236 |
201712 | 0.110 | 104.011 | 0.137 |
201803 | -0.260 | 105.290 | -0.320 |
201806 | 0.060 | 106.317 | 0.073 |
201809 | -0.020 | 106.507 | -0.024 |
201812 | 0.200 | 105.998 | 0.244 |
201903 | -0.070 | 107.251 | -0.084 |
201906 | 0.060 | 108.070 | 0.072 |
201909 | -0.150 | 108.329 | -0.179 |
201912 | -0.120 | 108.420 | -0.143 |
202003 | 0.190 | 108.902 | 0.226 |
202006 | -0.170 | 108.767 | -0.202 |
202009 | 2.940 | 109.815 | 3.465 |
202012 | 0.320 | 109.897 | 0.377 |
202103 | 0.230 | 111.754 | 0.266 |
202106 | 0.420 | 114.631 | 0.474 |
202109 | 0.390 | 115.734 | 0.436 |
202112 | -0.120 | 117.630 | -0.132 |
202203 | 0.150 | 121.301 | 0.160 |
202206 | 0.400 | 125.017 | 0.414 |
202209 | -0.020 | 125.227 | -0.021 |
202212 | -0.220 | 125.222 | -0.227 |
202303 | -0.430 | 127.348 | -0.437 |
202306 | 0.510 | 128.729 | 0.513 |
202309 | 0.230 | 129.860 | 0.229 |
202312 | 0.520 | 129.419 | 0.520 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Pacira BioSciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Marcelo Bigal | director | C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Abraham Ceesay | director | C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
Alethia Young | director | C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Michael J. Yang | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Roy Winston | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Lauren Bullaro Riker | officer: Executive Director, Accounting | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Kristen Marie Williams | officer: CAO and General Counsel | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Mark A. Kronenfeld | director | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054 |
Daryl Gaugler | officer: Chief Operating Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Reinhart Charles A. Iii | officer: Chief Financial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Ellis Ronald J. Jr. | officer: Chief Strategy Officer | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Max Reinhardt | officer: President | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
David M Stack | director, officer: President and CEO | THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Dennis Mcloughlin | officer: Chief Commercial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Jonathan Slonin | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
From GuruFocus
By sperokesalga sperokesalga • 03-22-2023
By Marketwired • 09-26-2023
By Value_Insider Value_Insider • 11-08-2022
By Marketwired • 10-02-2023
By Marketwired • 10-26-2023
By sperokesalga sperokesalga • 02-23-2023
By GuruFocus Research • 11-02-2023
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 03-29-2023